Literature DB >> 19123901

Retreatment of vestibular schwannomas with Gamma Knife surgery.

Sheri Dewan1, Georg Norén.   

Abstract

OBJECT: The response rate of vestibular schwannomas (VSs) to radiosurgery has reached the 97% level in several published series. When failure rarely occurs, some controversy has existed as to whether the tumor has to be resected or can be safely retreated with radiosurgery. The authors retrospectively studied the outcome of retreating 11 patients with Gamma Knife surgery (GKS).
METHODS: The authors studied 11 patients at the New England Gamma Knife Center who had undergone GKS as a second radiosurgical treatment for VS from 1994 to 2007. One patient underwent proton-beam radiotherapy as the first treatment, and the other 10 patients had undergone GKS initially. Tumor control (size before and after the first and the second treatment) was evaluated using MR imaging to demonstrate the course after the 2 treatments. Facial nerve function (House-Brackmann grading system), trigeminal nerve function, hearing (Gardner-Robertson classification), and any adverse radiation effects were evaluated. The prescription dose was 12 Gy (11-13.2 Gy) for both treatments.
RESULTS: Of the 11 patients, 2 showed increase, 1 had no change, and, in 8, the VS decreased in size after the retreatment. One tumor remained unchanged over the first 6 months, but demonstrated signs of internal necrosis. All patients demonstrated stable facial nerve function. Regarding facial numbness, 2 patients experienced increases, 8 no change, and 1 decreased numbness. There was no functional hearing prior to the second treatment in 10 patients, and hearing was impaired in 1 patient. Adverse radiation effects (slight peduncular edema) were seen in 2 patients after the second treatment, and 1 patient had edema after the first treatment as well.
CONCLUSIONS: Vestibular schwannomas can be retreated with GKS with good tumor control response and low risk of toxicity.

Entities:  

Mesh:

Year:  2008        PMID: 19123901     DOI: 10.3171/JNS/2008/109/12/S22

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  Role of stereotactic radiosurgery in meningiomas and vestibular schwannomas.

Authors:  Jeffrey T Jacob; Michael J Link; Bruce E Pollock
Journal:  Curr Treat Options Neurol       Date:  2014-08       Impact factor: 3.598

2.  Increased expression of EMMPRIN and VEGF in the rat brain after gamma irradiation.

Authors:  Ming Wei; Hong Li; Huiling Huang; Desheng Xu; Dashi Zhi; Dong Liu; Yipei Zhang
Journal:  J Korean Med Sci       Date:  2012-02-23       Impact factor: 2.153

3.  Repeat single-fraction stereotactic radiosurgery for recurrent vestibular schwannoma.

Authors:  Cooper T Rapp; Robert J Amdur; Frank J Bova; Kelly D Foote; William A Friedman
Journal:  Rep Pract Oncol Radiother       Date:  2022-09-19

4.  Increased CD147 and MMP-9 expression in the normal rat brain after gamma irradiation.

Authors:  Hong Li; Ming Wei; Shenghui Li; Ziwei Zhou; Desheng Xu
Journal:  J Radiat Res       Date:  2012-08-21       Impact factor: 2.724

5.  Repeat Gamma Knife surgery for vestibular schwannomas.

Authors:  Sarah Lonneville; Carine Delbrouck; Cécile Renier; Daniel Devriendt; Nicolas Massager
Journal:  Surg Neurol Int       Date:  2015-09-28

6.  A meta-analysis of treatment of vestibular schwannoma using Gamma Knife radiosurgery.

Authors:  Bartosz Rykaczewski; Miroslaw Zabek
Journal:  Contemp Oncol (Pozn)       Date:  2014-01-25

7.  Alterations in the expression of vascular endothelial growth factor in the rat brain following gamma knife surgery.

Authors:  Lei Cheng; Lin Ma; Hecheng Ren; Hongwei Zhao; Yiqiang Pang; Yongheng Wang; Ming Wei
Journal:  Mol Med Rep       Date:  2014-08-27       Impact factor: 2.952

Review 8.  Repeat stereotactic radiosurgery for progressive vestibular schwannomas after previous radiosurgery: a systematic review and meta-analysis.

Authors:  Anne Balossier; Jean Régis; Nicolas Reyns; Pierre-Hugues Roche; Roy Thomas Daniel; Mercy George; Mohamed Faouzi; Marc Levivier; Constantin Tuleasca
Journal:  Neurosurg Rev       Date:  2021-04-13       Impact factor: 3.042

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.